通过增强mTORC1信号传递,BACE2促进了肺腺癌的进展
Zhixin You1, Wei He1, Yanfei Zhou2
1Respiratory Department, Shaoxing Hospital of Traditional Chinese Medicine, Shaoxing, China.
Translational cancer research
|March 12, 2026
概括
β-分泌酶2 (BACE2) 通过激活mTORC1通路,促进肺腺癌 (LUAD) 的进展. 针对BACE2为LUAD患者提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症研究 癌症研究
背景情况:
- 肺腺癌 (LUAD) 是一个重大的临床挑战,因为它对传统疗法的耐药性.
- 识别新型瘤驱动因素和治疗点对于改善LUAD患者的治疗结果至关重要.
- 贝塔-分泌酶2 (BACE2) 在LUAD病原体中的作用在很大程度上仍未被探索.
研究的目的:
- 为了研究BACE2在LUAD中的表达模式.
- 阐明BACE2在LUAD中的生物学功能和潜在的分子机制.
- 评估BACE2作为LUAD潜在的治疗点.
主要方法:
- 生物信息分析和免疫组织化学被用来评估BACE2在LUAD组织和细胞系中的表达.
- 在体外试验 (CCK-8,EDU,流细胞计,Transwell,scratch) 评估了BACE2对细胞活力,增殖,亡,迁移和细胞周期的影响.
- 基因组丰富分析 (GSEA) 和西式涂抹识别了BACE2.2调节的下游信号通路.
- 使用一种体内异种移植模型来证实BACE2在瘤生长中的作用.
主要成果:
- 在LUAD组织和细胞系中,BACE2表达显著升高,与患者存活率较差相关.
- BACE2的淘汰导致了亡的增加,细胞活力,增殖和迁移的减少,以及G2阶段细胞周期的停止.
- BACE2激活了猛素复合体1 (mTORC1) 信号通路的哺乳动物点,这是GSEA和西方斑点分析所证明的.
- 抑制mTORC1取消了BACE2的瘤效应,而BACE2的淘汰抑制了体内瘤的生长.
结论:
- BACE2通过激活mTORC1信号通路,在促进LUAD进展方面发挥着至关重要的作用.
- BACE2代表了治疗肺腺癌的新且有前途的治疗标.
- 针对BACE2可能提供一种新的策略,以克服对现有的LUAD疗法的耐药性.
更多相关视频
10:32Combined Use of Tail Vein Metastasis Assays and Real-Time In Vivo Imaging to Quantify Breast Cancer Metastatic Colonization and Burden in the Lungs
Published on: December 19, 2019
11.7K
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.8K
相关概念视频
mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
mTOR Signaling and Cancer Progression
1.6K
1.6K
PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K
MAPK Signaling Cascades
9.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
Tumor Progression
7.7K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.7K
Tumor Progression
3.4K
3.4K
